CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 274 target
Drug / intervention
Quality-of-Life Assessment +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04650178
NCT04650178N/AActiveOn TrackUpdated 2mo ago

COVID-19: Well-Being in Cancer Patients With Neuropathy Who Participated in Prior Clinical Trials

M.D. Anderson Cancer Center·observational·Posted Dec 2, 2020·Updated Apr 27, 2026

In Brief

An observational study evaluating Quality-of-Life Assessment and Questionnaire Administration for COVID-19 Infection and 3 related conditions. Active but no longer recruiting, targeting 274 participants across 1 site.

Detailed Summary

This study investigates the experiences of cancer patients with neuropathy during the COVID-19 pandemic to learn how the COVID-19 pandemic affects their quality of life and clinical outcomes. This study will also explore whether there are differences between patients who received neurofeedback (NFB, a type of therapy that is thought to help normalize brain activity) and those who did not. Learning about quality of life in cancer patients with neuropathy during the COVID-19 pandemic may help guide development of programs and policies to improve chronic pain patient care and outcomes during a major global healthcare crisis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/AActive
2021202220232024202520262027
First PostedDec 2, 2020
Enrollment StartMay 26, 2020
Primary CompletionApr 30, 2027
TodayJul 1, 2026
Enrollment to primary: 6.9 yearsPosted 5.6 years agoPrimary completion in 10 months

Interventions

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Complete questionnaire